Patients with advanced solid tumours known to express Nectin-4 will be enrolled in the study. Credit: RAGIB33 / Shutterstock.

Innate Pharma has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase I trial of IPH4502 for solid tumours.

IPH4502 is a topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase I study, set to commence in the next few months, is designed as an open-label, multicentre trial.

It will be conducted in two parts: part one dose escalation and part two dose optimisation.

The trial aims to evaluate the tolerability, safety and initial efficacy of IPH4502 when administered as a single agent.

Patients with advanced solid tumours known to express Nectin-4 will be enrolled in the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These include, but are not limited to, people with urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, and colorectal cancers.

Nectin-4 is a cell membrane adhesion protein that is overexpressed in several types of solid tumours such as urothelial, breast, oesophageal, lung, ovarian, and pancreatic cancers.

It is notably less expressed in normal tissues, making it a promising target for cancer therapy.

IPH4502 showed significant anti-tumour efficacy both in vitro and in vivo in non-clinical models.

Innate Pharma chief medical officer Dr Sonia Quaratino said: “We are thrilled to advance the IPH4502 programme, and the IND application acceptance is an important milestone for Innate, as this is our first ADC programme to enter the clinic.

“IPH4502 is a novel and differentiated Nectin-4 ADC that has the potential to provide a new therapeutic option for patients with a cancer expressing a wide range of Nectin-4. Through this Phase I study, we aim to advance the research on our ADC technology for the benefit of patients.”